NCT04865237 - SARS-CoV-2 Human Challenge Characterisation Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 6, 2021

Primary Completion Date

July 11, 2022

Study Completion Date

July 11, 2022

Conditions

Covid19SARS-CoV InfectionCorona Virus InfectionCoronavirusCOVID-19

Interventions

BIOLOGICAL

SARS-CoV-2 Virus 1x10^1 TCID50

SARS-CoV-2, intranasally, (1x10\^1 TCID50)

DRUG

Remdesivir

VEKLURY™

BIOLOGICAL

SARS-CoV-2 Virus 1x10^2 TCID50

SARS-CoV-2, intranasally, (1x10\^2 TCID50)

BIOLOGICAL

SARS-CoV-2 Virus 1x10^3 TCID50

SARS-CoV-2, intranasally, (1x10\^3 TCID50)

Trial Locations (2)

hVIVO Services Ltd, QMB Bioenterprise building, London

Royal Free Foundation Hospital, London